OncoMatch/Clinical Trials/NCT05846750

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Is NCT05846750 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and lenalidomide for marginal zone lymphoma.

Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT05846750Data as of May 2026

Treatment: Obinutuzumab · lenalidomide — This is a prospective, multicenter clinical study that will enroll 59 patients with relapsed and refractory (R/R) MZL. The study is designed to evaluate the efficacy and safety of the combination of obinutuzumab and lenalidomide in the treatment of relapsed and refractory marginal zone lymphoma (MZL).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: systemic lymphoma therapy

Prior treatment with at least one line of systemic lymphoma including prior immunotherapy or chemoimmunotherapy

Cannot have received: lenalidomide (lenalidomide)

Exception: not refractory or resistant

Patients who are refractory or resistant to lenalidomide

Cannot have received: obinutuzumab (obinutuzumab)

Exception: not refractory or resistant

Patients who are refractory or resistant to obinutuzumab

Cannot have received: thalidomide (thalidomide)

Previous ≥ Grade 3 allergic reactions/Hypersensitivity to thalidomide

Lab requirements

Blood counts

Hemoglobin ≥ 7 g/dL; Absolute neutrophil count ≥ 1.0 × 10^9/L; Platelet count ≥ 50 x 10^9/L

Kidney function

Creatinine clearance ≥ 30 mL/min

Liver function

Glutathione transaminase(AST) or glutathione aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ≤ 2 × ULN (≤ 3 × ULN in patients with Gilbert's syndrome)

Adequate blood function... Hemoglobin ≥ 7 g/dL; Absolute neutrophil count ≥ 1.0 × 10^9/L; Platelet count ≥ 50 x 10^9/L; Creatinine clearance ≥ 30 mL/min; Glutathione transaminase(AST) or glutathione aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ≤ 2 × ULN (≤ 3 × ULN in patients with Gilbert's syndrome)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify